Novartis (SWX:NOVN) Could Be 9% Undervalued As Trial Setback Hits Shares

Novartis (SWX:NOVN) is under pressure after the Phase III HARBOR trial of delpacibart etedesiran in myotonic dystrophy type 1 missed its primary endpoint, a setback that triggered a sharp share price reaction.

That disappointment landed on top of an already bruising week for Novartis, with the 7-day share price return down about 13.5% and the 30-day share price return lower by roughly 9.8% as investors reassessed pipeline risk after back-to-back late-stage trial failures. Yet over a longer stretch, total shareholder return tells a different story. The 1-year gain is about 16.8% and the 5-year total shareholder return is roughly 83.6%, so recent momentum has clearly faded even as long-term holders have still seen substantial value created.

Spot fresh ideas beyond Novartis by scanning a hand picked group of resilient healthcare and pharma players in our 97 resilient stocks with low risk scores.

After a drop of more than 13% in a week, Novartis now sits at a very different entry point than it did a month ago. Does it make more sense to lean in here or stay patient for cheaper levels?

Most Popular Narrative: 8.8% Undervalued

On the latest figures, the most followed fair value estimate for Novartis sits at CHF122.87, compared with a last close of CHF112.04. This frames the recent pullback against a still supportive narrative built on earnings, margins and cash generation assumptions.

Operational efficiency gains from portfolio streamlining (e.g., previous spin-offs and exiting non-core lines) and productivity improvements are driving core margin expansion and higher free cash flow. This can be reinvested in R&D and shareholder returns, supporting long-term earnings and net margin growth.

Read the complete narrative. Read the complete narrative.

Want to see what is behind that margin story? The fair value hinges on how fast revenue compounds, how wide profits get, and what multiple investors pay for those earnings. Curious which assumptions really move that CHF122.87 figure.

Result: Fair Value of CHF122.87 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the Novartis story can break if generic pressure on key drugs like Entresto bites harder than expected or late stage trials continue to disappoint.

Find out about the key risks to this Novartis narrative.

Next Steps

Mixed feelings on Novartis after this week. If you want to move fast but think independently, compare the 4 key rewards and 1 important warning sign with your own judgment.

Looking for more ideas beyond Novartis?

Do not stop with Novartis. Broaden your watchlist with other high quality opportunities so you are not relying on a single story to carry your returns.

• Target resilient potential by scanning a 97 resilient stocks with low risk scores that can help anchor your portfolio when sentiment swings.
• Hunt for mispriced quality through a 183 high quality undervalued stocks that highlights companies where fundamentals and price look out of sync.
• Build a reliable income stream with a 164 dividend fortresses that focuses on higher yielding businesses with the potential to support regular payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com